Skip to main content
Terug
AKBLF logo

ALK-Abelló A/S

Datakwaliteit: 100%
Oversold
AKBLF
OTC Healthcare Biotechnology
€ 32,18
€ 0,00 (0,00%)
Marktkapitalisatie: 6,48B
Dagbereik
€ 32,18 € 36,10
52-Weeksbereik
€ 19,90 € 36,14
Volume
100
50D / 200D Gem.
€ 35,21 / € 32,30
Vorige Slotkoers
€ 32,18

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 5,4 0,4
P/B 1,0 2,9
ROE % 20,2 3,7
Net Margin % 19,0 3,9
Rev Growth 5Y % 12,6 10,0
D/E 0,1 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 0,00
€ 0,00 – € 0,00
 10 B 0
FY2029 € 9,86
€ 9,77 – € 9,95
 10 B 1
FY2028 € 8,00
€ 7,92 – € 8,07
 9 B 1

Belangrijkste Punten

Revenue grew 12,61% annually over 5 years — strong growth
Earnings grew 46,54% over the past year
ROE of 20,24% indicates high profitability
Net margin of 18,96% shows strong profitability
Debt/Equity of 0,07 — conservative balance sheet
Generating 1,54B in free cash flow

Groei

Revenue Growth (5Y)
12,61%
Revenue (1Y)13,74%
Earnings (1Y)46,54%
FCF Growth (3Y)131,05%

Kwaliteit

Return on Equity
20,24%
ROIC18,17%
Net Margin18,96%
Op. Margin26,35%

Veiligheid

Debt / Equity
0,07
Current Ratio3,38
Interest Coverage72,30

Waardering

P/E Ratio
5,42
P/B Ratio1,01
EV/EBITDA3,41
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13,74% Revenue Growth (3Y) 14,26%
Earnings Growth (1Y) 46,54% Earnings Growth (3Y) 56,76%
Revenue Growth (5Y) 12,61% Earnings Growth (5Y) 52,82%
Profitability
Revenue (TTM) 6,30B Net Income (TTM) 1,19B
ROE 20,24% ROA 13,05%
Gross Margin 65,87% Operating Margin 26,35%
Net Margin 18,96% Free Cash Flow (TTM) 1,54B
ROIC 18,17% FCF Growth (3Y) 131,05%
Safety
Debt / Equity 0,07 Current Ratio 3,38
Interest Coverage 72,30 Dividend Yield 0,00%
Valuation
P/E Ratio 5,42 P/B Ratio 1,01
P/S Ratio 1,03 PEG Ratio 0,91
EV/EBITDA 3,41 Dividend Yield 0,00%
Market Cap 6,48B Enterprise Value 5,66B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6,30B 5,54B 4,82B 4,51B 3,92B
Net Income 1,19B 815,00M 486,00M 335,00M 219,00M
EPS (Diluted) 5,41 3,68 2,20 1,51 0,99
Gross Profit 4,15B 3,55B 3,04B 2,79B 2,40B
Operating Income 1,66B 1,09B 666,00M 470,00M 292,00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9,15B 8,25B 6,73B 6,31B 5,83B
Total Liabilities 2,72B 2,87B 2,28B 2,32B 2,35B
Shareholders' Equity 6,43B 5,37B 4,45B 3,99B 3,48B
Total Debt 418,00M 1,19B 765,00M 696,00M 710,00M
Cash & Equivalents 1,24B 589,00M 474,00M 221,00M 194,00M
Current Assets 4,48B 3,29B 2,97B 2,65B 2,40B
Current Liabilities 1,33B 1,95B 1,31B 1,40B 1,39B

Strategiescores

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#601 of 1052
41
Custom Capital Light Compounder
#86 of 219
46
Custom Contrarian Investing (David Dreman)
#126 of 670
52
Growth Growth Investing (Philip Fisher)
#151 of 156
15
Value Value Investing (Warren Buffett)
#155 of 203
33
Custom Balanced Risk
#101 of 152
42
Custom Lower Risk
#130 of 141
28

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Growth Investing (Philip Fisher)
Mar 24, 2026
Ingestapt Value Investing (Warren Buffett)
Mar 24, 2026
Ingestapt Balanced Risk
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026